Art

J-GLOBAL ID：201702239089970110   Reference number：17A0556792

Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C

慢性C型肝炎の高齢患者に対するダクラタスビルとアスナプレビルによる二剤併用療法の安全性と有効性

Author (21)： MORIO Reona (Hiroshima Univ., Hiroshima, JPN) ,  IMAMURA Michio (Hiroshima Univ., Hiroshima, JPN) ,  KAWAKAMI Yoshiiku (Hiroshima Univ., Hiroshima, JPN) ,  MORIO Kei (Hiroshima Univ., Hiroshima, JPN) ,  KOBAYASHI Tomoki (Hiroshima Univ., Hiroshima, JPN) ,  YOKOYAMA Satoe (Hiroshima Univ., Hiroshima, JPN) ,  KIMURA Yuki (Hiroshima Univ., Hiroshima, JPN) ,  NAGAOKI Yuko (Hiroshima Univ., Hiroshima, JPN) ,  KAWAOKA Tomokazu (Hiroshima Univ., Hiroshima, JPN) ,  TSUGE Masataka (Hiroshima Univ., Hiroshima, JPN) ,  HIRAMATSU Akira (Hiroshima Univ., Hiroshima, JPN) ,  HAYES C. Nelson (Hiroshima Univ., Hiroshima, JPN) ,  AIKATA Hiroshi (Hiroshima Univ., Hiroshima, JPN) ,  TAKAHASHI Shoichi (Hiroshima Univ., Hiroshima, JPN) ,  MIKI Daiki (Inst. of Physical and Chemical Res. (RIKEN), Hiroshima, JPN) ,  OCHI Hidenori (Inst. of Physical and Chemical Res. (RIKEN), Hiroshima, JPN) ,  MORI Nami (Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, JPN) ,  TAKAKI Shintaro (Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, JPN) ,  TSUJI Keiji (Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, JPN) ,  CHAYAMA Kazuaki (Hiroshima Univ., Hiroshima, JPN) ,  CHAYAMA Kazuaki (Inst. of Physical and Chemical Res. (RIKEN), Hiroshima, JPN)
Material： Journal of Gastroenterology  (J Gastroenterol)
Volume： 52  Issue： 4  Page： 504-511  Publication year： 2017 
JST Material Number： Z0748A  ISSN： 0944-1174  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： HCV1 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0556792&from=J-GLOBAL&jstjournalNo=Z0748A") }}

JST classification (4)： Treatment for infectious diseases,parasitic diseases.  (GD01030D) ,  Digestive system diseases  (GH03000W) ,  Drug therapy(=pharmacotherapy)for digestive system diseases  (GH05020G) ,  Clinical application of antiviral drugs  (GW17050Z)

Substance index (2)： BMS-650032 ,  BMS-790052

Reference (30)：

• Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-14.
• Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis. 2010;201:751-9.
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
• McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-93.
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16.

Terms in the title (7)： 慢性C型肝炎 ,  高齢患者 ,  ダクラタスビル ,  アスナプレビル ,  併用療法 ,  安全性 ,  有効性